Nimotuzumab with chemo and radiation for advanced nose cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding nimotuzumab (an anti-EGFR antibody) to standard chemotherapy and radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. It may help the cancer respond better and control it more effectively after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 70
- Your nose cancer type is non-keratinizing carcinoma
- Your cancer is stage III to IV (with an exception for T3N0) and can be measured on scans
- Your general health is good enough (ECOG 0 to 1)
- Your blood counts, liver tests, and kidney function are within required ranges
- You have not had surgery to remove the main tumor or lymph nodes (except a biopsy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy (GP), nimotuzumab, and sintilimab before standard treatment for locally advanced nasopharyngeal cancer. It aims to see if this approach can improve outcomes.
This trial tests a combination of chemotherapy with two additional drugs (nimotuzumab and toripalimab) for people with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard therapy.
This trial tests a combination of three drugs—an anti-PD1 immunotherapy, nimotuzumab (targets EGFR), and capecitabine (chemotherapy)—for people whose nasopharyngeal cancer has returned or spread and no longer responds to platinum-based chemotherapy. The goal is to see if this combination can help when standard treatment stops working.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Hear when a new Nasopharyngeal Carcinoma by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.